VistaGen Therapeutics
VTGN
11 hedge funds and large institutions have $6.94M invested in VistaGen Therapeutics in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.38M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
+$1.35M |
| 3 |
Parallax Volatility Advisers
San Francisco,
California
|
+$1.12M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.12M |
| 5 |
NC
Nexthera Capital
New York
|
+$528K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $2.43M | +$2.38M | +20,777 | New |
|
|
NLVP
2
New Leaf Venture Partners
New York
| $1.38M | +$1.35M | +11,765 | New |
|
|
3
Parallax Volatility Advisers
San Francisco,
California
| $1.15M | +$1.12M | +9,803 | New |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $1.15M | +$1.12M | +9,803 | New |
|
|
NC
5
Nexthera Capital
New York
| $539K | +$528K | +4,604 | New |
|
|
DCM
6
DAFNA Capital Management
Los Angeles,
California
| $183K | +$179K | +1,563 | New |
|
7
HighTower Advisors
Chicago,
Illinois
| $79K | +$77.2K | +674 | New |
|
|
LTFS
8
Ladenburg Thalmann Financial Services
Miami,
Florida
| $29K | +$28.4K | +248 | New |
|
|
HFM
9
Hartford Financial Management
Hartford,
Connecticut
| $4K | +$4.24K | +37 | New |
|
10
Bank of America
Charlotte,
North Carolina
| $3K | +$2.52K | +22 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | +$344 | +3 | New |
|
VTGN Hedge Fund Activity: Q2 2016 in Review
11 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2016, worth a combined $6.94M.
Buyers outnumbered sellers: 11 funds opened new VTGN positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.38M.
- 11 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2016, up from 0 in Q1 2016.
- Funds reported $6.94M of VistaGen Therapeutics stock for Q2 2016.
- 11 funds opened new VistaGen Therapeutics positions in Q2 2016 and 0 closed out, a net change of +11 holders.
- The largest VistaGen Therapeutics buyer in Q2 2016 was Sabby Management, an estimated $2.38M added.
Based on aggregated 13F filings for Q2 2016.